Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

PCI before TAVR? In older CAD patients, deferral may be the best approach
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
Whoop raises $575M—Abbott, LeBron James, Cristiano Ronaldo among the investors
Whoop, a Boston-based wearable technologies company, raised the new funding on a $10.1 billion evaluation.
Interventional cardiologist Roxana Mehran elected ACC president
A prominent figure in the fields of interventional cardiology and women’s health is now leading the American College of Cardiology.
New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel
A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.
FDA clears new AI model for pulmonary hypertension
The advanced algorithm, which previously received the FDA's breakthrough device designation, detects signs of pulmonary hypertension in standard 12-lead electrocardiograms.

Michiel Voskuil, MD, PhD, an interventional cardiologist and professor at University Medical Center Utrecht in the Netherlands, presented his team’s data on the ACC.26 stage.

PCI before TAVR? In older CAD patients, deferral may be the best approach

Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.

Whoop, a Boston-based wearable technologies company, has raised $575 million in new financing at a $10.1 billion valuation. Investors include Abbott, Mayo Clinic, LeBron James and Cristiano Ronaldo.

Whoop raises $575M—Abbott, LeBron James, Cristiano Ronaldo among the investors

Whoop, a Boston-based wearable technologies company, raised the new funding on a $10.1 billion evaluation.

Interventional cardiologist Roxana Mehran, MD, officially started her one-year term as the president of the American College of Cardiology (ACC) on the closing day of ACC.26, the group’s annual conference in New Orleans.

Interventional cardiologist Roxana Mehran elected ACC president

A prominent figure in the fields of interventional cardiology and women’s health is now leading the American College of Cardiology.

Adam Greenbaum, MD, presents late-breaking data at ACC.26.

New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel

A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.

AI model algorithm tablet digital patient data

FDA clears new AI model for pulmonary hypertension

The advanced algorithm, which previously received the FDA's breakthrough device designation, detects signs of pulmonary hypertension in standard 12-lead electrocardiograms.

Medical malpractice gavel diagnostic error mistake stethoscope

Patient injected with acid instead of saline earns undisclosed settlement

The disturbing case highlights a series of process errors and cost-cutting measures that ultimately led to the “never event” accident.

‘Practice-changing’ interventional cardiology research grabs ACC.26 spotlight

The second day of the American College of Cardiology’s annual conference started with a series of highly anticipated interventional cardiology trials.

Stavros V. Konstantinides, MD, PhD, presenting data at ACC.26

Catheter-based treatment linked to major benefits for intermediate-risk PE

New 30-day data presented at ACC.26 helped answer questions cardiologists have had been asking for years. “Thank you for bringing PE into the future," one vascular specialist said from the stage.